Review of publications on drug-related problems investigations in osteoporosis patients

A chronic form of osteoporosis (OP) substantiates a long-term pharmacotherapy of patients, which increases the risk of adverse drug reactions (ADRs) during the therapy. The enhancement of requirements to the quality of safety monitoring carried out in the context of pharmacovigilance and the newly identified safety problems require an improvement of the system of quality control of medicinal products (MPs).

The aim of the work was to review the application of a new promising method for monitoring the drug safety – the system of Drug-Related Problems (DRP) in the osteoporosis pharmacotherapy.

Materials and methods. The following databases and search engines were used to retrieve scientific papers by Russian and foreign authors: PubMed, elibrary.ru, Google Scholar, CyberLeninka, Russian National Library. The information sources were searched using the following keywords and word combinations: “drug-related problems”, “drug safety”, “osteoporosis” (in Russian and English, respectively), as well as the corresponding MeSH terms.

Results. The application of DRP system in the health care of different countries was reviewed, and the risk factors of the problems associated with the use of MPs, the appropriate interventions in case of the detection of high DRP values were investigated. The study of the problems associated with the use of MPs for the treatment of OP during the complex pharmacotherapy made it possible to determine the feasibility of using this method to improve the safety and effectiveness of this kind of treatment in patients.

Conclusion. The analysis of emerging DRPs makes it possible to increase patients’ adherence to the treatment and stop the ADRs. This improves the quality of life of patients and increases the effectiveness of pharmacotherapy. The introduction of such a method of the drug safety research into the system of pharmacovigilance of the Russian Federation is an important step in the development of personalized medicine. A further study of problems associated with the use of drugs in OP patients will also help to reduce the risks arising during the combination pharmacotherapy.

1. Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. The incidence of usculoskeletal diseases in the Russian Federation over 2015–2016. Rheumatology Science and Practice. 2018;56(1):15–21. DOI: 10.14412/1995-4484-2018-15-21. Russian

2. Titova LV, Makarova MV, Smirnova AA, Obukhova IV, Ivanova SN. The epidemiological characteristic of diseases of musculoskeletal system. Healthcare of the Russian Federation. 2018;62(1):13–7. DOI: 10.18821/0044-197Х-2018-62-1-13-17. Russian

3. Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Modern Rheumatology Journal. 2019;13(4):11–7. DOI: 10.14412/1996-7012-2019-4-11-17. Russian

4. Chelishcheva MY. Working conditions and incidence of diseases of the musculoskeletal system of metallurgists. Occupational medicine and industrial ecology. 2009;(10):31–6. Russian

5. Oleynikova TA, Pozhidaeva DN, Oreshko AYu. Prevalence survey of musculoskeletal and connective tissue disorders in the Russian Federation. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(1):5–13. DOI: 10.17749/2070-4909.2019.12.1.5-13. Russian

6. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–50. DOI: 10.1016/0002-9343(93)90218-e

7. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43. DOI: 10.1007/s11657-017-0324-5

8. Sözen T, Özışık L, Başaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46–56. DOI: 10.5152/eurjrheum.2016.048

9. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33. DOI: 10.1007/s00198-006-0172-4

10. Kravtsov VI, Akhverdyan YuR, Fofanova NA. Prevalence and risk factors of osteoporosis in the Volgograd region. Modern scientific research: problems and prospects. Modern scientific research: problems and prospects: Proceedings of the international scientific and practical conference. Ufa; 2015. P. 192–195. Russian

11. Fomina LA, Zyabreva IA. Epidemiology of osteoporosis and osteopenia. Tver Medical Journal. 2015;(1):63–73. Russian

12. Verbovoy AF, Pashentseva AV, Sharonova LA. Osteoporosis: Current state of the art. Terapevticheskii arkhiv. 2017;89(5):90–7. DOI: 10.17116/terarkh201789590-97. Russian

13. Lesnyak Lesnyak OM, Baranova IA, Belova KYu, Gladkova EN, Evstigneeva LP, Ershova OB, Karonova TL, Kochish AYu, Nikitinskaya OA, Skripnikova IA, Toroptsova NV, Aramisova RM. Osteoporosis in Russian Federation: epidemiology, socio-medical and economical aspects (review). Traumatology and Orthopedics of Russia. 2018;24(1):155–68. DOI: 10.21823/2311-2905-2018-24-1-155-168. Russian

14. Glagolev SV, Gorelov KV, Chizhova DA. Russian pharmacovigilance in a newly regulated environment: two-year results and prospects. Remedium. 2019;(3):8–14. DOI: 10.21518/1561-5936-2019-3-8-14. Russian

15. Olefir YuV, Romanov BK, Alyautdin RN, Lepakhin VK, Krasheninnikov AE, Shubnikova EV. Assessment of Pharmacovigilance Reporting in Russia. Safety and Risk of Pharmacotherapy. 2018;6(4):150–4. DOI: 10.30895/2312-7821-2018-6-4-150-154. Russian

16. Matveev AV, Krasheninnikov AE, Egorova EA, Konyaeva EI. Application of drug-related problems approach to analysis of non-steroidal anti-inflammatory drugs’ safety. Pharmacy & Pharmacology. 2019;7(4):215–23. DOI: 10.19163/2307-9266-2019-7-4-215-223

17. Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol. 2017;8:52. DOI: 10.1186/s40360-017-0157-2

18. Fog AF, Kvalvaag G, Engedal K, Straand J. Drug-related problems and changes in drug utilization after medication reviews in nursing homes in Oslo, Norway. Scand J Prim Health Care. 2017;35(4):329–35. DOI: 10.1080/02813432.2017.1397246

19. Ayalew MB, Megersa TN, Mengistu YT. Drug-related problems in medical wards of Tikur Anbessa specialized hospital, Ethiopia. J ResPharmPract. 2015;4(4):216–21. DOI: 10.4103/2279-042X.167048

20. Matveev AV, Krasheninnikov AE, Egorova EA, Koniaeva EI. Retrospective analysis of adverse drug reaction reporting forms associated with penicillin family antibiotics (pcne-drp 9.0) based on drug-related approach. Pharmacy & Pharmacology. 2020;8(1):57–64. DOI: 10.19163/2307-9266-2020-8-1-57-64

21. Matveev AV, Egorova EA, Konyaeva EI, Bekirova EYu, Adjimamutova LA. Study of the safety of antianemic preparations by method of the system of problems related to medicinal preparations. Pharmacy & Pharmacology. 2021;9(1):73–83. DOI: 10.19163/2307-9266-2021-9-1-73-83

22. Chernov AA, Kleymenova EB, Sychev DA, Abilmazhinova AA, Yashina LP, Otdelenov VA, Payushchik SA. Causes of hemorrhagic complications in hospitalized patients receiving therapeutic doses of anticoagulants. Clinical pharmacology and therapy. 2018;27(5):23–9. DOI: 10.32756/0869-5490-2018-5-23-29. Russian

23. Page MJ, McKenzie JE, Bossuyt PM Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71

24. Rootman I. Drug-related problems and the physician: the calgary experience. Can Fam Physician. 1973;19(11):66–8.

25. American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816–7. DOI: 10.1592/phco.28.6.816

26. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990;24(11):1093–97. DOI: 10.1177/106002809002401114

27. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9. DOI: 10.1136/bmj.329.7456.15

28. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–47. DOI: 10.1111/j.1365-2125.2006.02698.x

29. Delgado Silveira E, Fernandez-Villalba EM, García-Mina Freire M, Albiñana Pérez MS, Casajús Lagranja MP, Peris Martí JF. Impacto de la Intervención Farmacéutica en el tratamientodel paciente mayor pluripatológico [The impact of Pharmacy Intervention on the treatment of elderly multi-pathological patients]. Farm Hosp. 2015;39(4):192–202. DOI: 10.7399/fh.2015.39.4.8329. Spanish

30. Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26(6):399–406. DOI: 10.1016/j.ejim.2015.05.012

31. Bedouch P, Sylvoz N, Charpiat B, Juste M, Roubille R, Rose FX, Bosson JL, Conort O, Allenet B; French Society of Clinical Pharmacy’s Act-IP© Group. Trends in pharmacists’ medication order review in French hospitals from 2006 to 2009: analysis of pharmacists’ interventions from the Act-IP© website observatory. J Clin Pharm Ther. 2015;40(1):32–40. DOI: 10.1111/jcpt.12214

32. Shanika LGT, Coombes J, Perera D, Mohamed F, Coombes I, De Silva HA, Dawson AH. Ward-based clinical pharmacists and hospital readmission: a non-randomized controlled trial in Sri Lanka. Bull. World Health Organ. 2018;96:155–64. DOI: 10.2471/BLT.17.198366. Erratum in: Bull World Health Organ. 2018;96(5):368.

33. Stuhec M, Bratović N, Mrhar A. Impact of clinical pharmacist’s interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: A prospective non-randomized study. Sci Rep. 2019;9(1):16856. DOI: 10.1038/s41598-019-53057-w

34. Tefera GM, Zeleke AZ, Jima YM, Kebede TM. Drug Therapy Problems and the Role of Clinical Pharmacist in Surgery Ward: Prospective Observational and Interventional Study. Drug Healthc Patient Saf. 2020;12:71–83. DOI: 10.2147/DHPS.S251200

35. Kaufmann CP, Stämpfli D, Hersberger KE, Lampert ML. Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open. 2015;5(3):e006376. DOI: 10.1136/bmjopen-2014-006376

36. Keijsers CJ, Leendertse AJ, Faber A, Brouwers JR, de Wildt DJ, Jansen PA. Pharmacists’ and general practitioners’ pharmacology knowledge and pharmacotherapy skills. J Clin Pharmacol. 2015;55(8):936–43. DOI: 10.1002/jcph.500

37. Freyer J, Hueter L, Kasprick L, Frese T, Sultzer R, Schiek S, Bertsche T. Drug-related problems in geriatric rehabilitation patients after discharge - A prevalence analysis and clinical case scenario-based pilot study. Res Social Adm Pharm. 2018;14(7):628–37. DOI: 10.1016/j.sapharm.2017.07.009

38. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407. DOI: 10.2165/00002018-200730050-00003

39. Abunahlah N, Elawaisi A, Velibeyoglu FM, Sancar M. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey. Int J Clin Pharm. 2018;40(2):360–7. DOI: 10.1007/s11096-017-0585-5

40. Blix HS, Viktil KK, Reikvam A, Moger TA, Hjemaas BJ, Pretsch P, Vraalsen TF, Walseth EK. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol. 2004;60(9):651–8. DOI: 10.1007/s00228-004-0830-4

41. Garin N, Sole N, Lucas B, Matas L, Moras D, Rodrigo-Troyano A, Gras-Martin L, Fonts N. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11(1):883. DOI: 10.1038/s41598-020-80560-2

42. Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. 2022;237:108168. DOI: 10.1016/j.pharmthera.2022.108168

43. Khandelwal S, Lane NE. Osteoporosis: Review of etiology, mechanisms, and approach to management in the aging population. Endocrinol Metab Clin North Am. 2023;52(2):259–75. DOI: 10.1016/j.ecl.2022.10.009

44. Zhu Z, Yu P, Wu Y, Wu Y, Tan Z, Ling J, Ma J, Zhang J, Zhu W, Liu X. Sex Specific Global Burden of Osteoporosis in 204 Countries and Territories, from 1990 to 2030: An Age-Period-Cohort Modeling Study. J Nutr Health Aging. 2023;27(9):767–74. DOI: 10.1007/s12603-023-1971-4

45. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–76. DOI: 10.1016/S0140-6736(18)32112-3

46. Walker MD, Shane E. Postmenopausal Osteoporosis. N Engl J Med. 2023;389(21):1979–91. DOI: 10.1056/NEJMcp2307353

47. Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C; Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group. A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr. 2016;16(1):158. DOI: 10.1186/s12877-016-0332-0

48. Savchenko TN, Agaeva MI, Nosova LA, Shapovalova YuO. Prevention of osteoporosis in women. RMJ. 2017;12:879–83. Russian

49. Oryan A, Sahvieh S. Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life Sci. 2021;264:118681. DOI: 10.1016/j.lfs.2020.118681

50. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13–20. DOI: 10.1016/j.amjmed.2012.06.023

51. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45. DOI: 10.4065/83.9.1032

52. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2016;31(1):16–35. DOI: 10.1002/jbmr.2708

53. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91. DOI: 10.1359/jbmr.0707onj

54. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94. DOI: 10.1002/jbmr.253

55. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–37. DOI: 10.1056/NEJMoa1010650

56. Chen W, Zhang H, Jiang J, Zhang X, Ding J, Liu Y, Dang H. Application of comprehensive pharmaceutical care program in identifying and addressing drug-related problems in hospitalized patients with osteoporosis. BMC Health Serv Res. 2022;22(1):1438. DOI: 10.1186/s12913-022-08862-x

57. Ilić D, Bukumirić Z, Janković S. Drug-related problems in patients with osteoporosis. Vojnosanit Pregl. 2016;73(3):261–5. DOI: 10.2298/vsp140909090i

58. Linden-Lahti C, Takala A, Holmström AR, Airaksinen M. Applicability of drug-related problem (DRP) classification system for classifying severe medication errors. BMC Health Serv Res. 2023;23:743. DOI: 10.1186/s12913-023-09763-3